Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Elaine Lam

Concepts (314)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Renal Cell
37
2026
234
7.040
 Why?
Kidney Neoplasms
40
2026
412
6.600
 Why?
Prostatic Neoplasms
13
2023
974
2.840
 Why?
Neoplasms, Germ Cell and Embryonal
3
2023
75
1.440
 Why?
Antineoplastic Agents
15
2024
2194
1.300
 Why?
Prostate-Specific Antigen
4
2023
161
1.150
 Why?
Antibodies, Monoclonal, Humanized
12
2025
985
1.120
 Why?
Protein Kinase Inhibitors
12
2026
969
1.030
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2025
1953
1.000
 Why?
Testicular Neoplasms
3
2023
113
0.910
 Why?
Neoplasms, Unknown Primary
1
2025
20
0.900
 Why?
Neoplasms
10
2023
2875
0.900
 Why?
Antineoplastic Agents, Immunological
2
2025
199
0.840
 Why?
Carcinoma, Transitional Cell
4
2025
68
0.800
 Why?
Seminoma
2
2021
20
0.780
 Why?
Carcinoma, Medullary
2
2013
16
0.710
 Why?
Aged
37
2026
25913
0.690
 Why?
Retroperitoneal Neoplasms
1
2021
28
0.670
 Why?
Urinary Bladder Neoplasms
4
2025
255
0.660
 Why?
Male
60
2026
72315
0.650
 Why?
Pyridines
6
2026
605
0.640
 Why?
Teratoma
1
2021
120
0.630
 Why?
Pneumocystis carinii
1
2020
12
0.630
 Why?
Spinal Cord Compression
1
2020
22
0.630
 Why?
Carcinoma, Squamous Cell
1
2025
641
0.630
 Why?
Trimethoprim, Sulfamethoxazole Drug Combination
1
2020
42
0.620
 Why?
Pneumonia, Pneumocystis
1
2020
34
0.620
 Why?
Euterpe
1
2018
4
0.580
 Why?
Humans
87
2026
144759
0.580
 Why?
Middle Aged
39
2026
35875
0.540
 Why?
TWEAK Receptor
1
2017
6
0.540
 Why?
Prednisone
3
2020
221
0.540
 Why?
Pyrazoles
3
2022
509
0.520
 Why?
Anilides
5
2023
84
0.520
 Why?
Abiraterone Acetate
1
2017
15
0.510
 Why?
Sulfonamides
3
2015
580
0.510
 Why?
Biomarkers, Tumor
6
2025
1313
0.500
 Why?
Plant Extracts
1
2018
187
0.500
 Why?
Adrenal Cortex Hormones
1
2020
478
0.500
 Why?
Aged, 80 and over
17
2025
8265
0.480
 Why?
Antineoplastic Agents, Hormonal
2
2015
194
0.460
 Why?
Neoplasm Metastasis
9
2020
688
0.460
 Why?
Neoplasm Recurrence, Local
3
2023
1137
0.460
 Why?
Carcinoma, Papillary
1
2015
79
0.440
 Why?
Brain Neoplasms
2
2021
1318
0.440
 Why?
Paclitaxel
3
2022
255
0.420
 Why?
Everolimus
2
2025
111
0.420
 Why?
Patient Reported Outcome Measures
4
2025
488
0.420
 Why?
Prostatic Neoplasms, Castration-Resistant
3
2022
53
0.410
 Why?
Interleukin-2
2
2014
437
0.410
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.410
 Why?
Antibodies, Monoclonal
2
2017
1519
0.380
 Why?
Urologic Neoplasms
2
2025
31
0.370
 Why?
Nephrectomy
4
2024
158
0.360
 Why?
Treatment Outcome
17
2025
11679
0.360
 Why?
Retrospective Studies
18
2024
17066
0.360
 Why?
Epothilones
1
2011
2
0.350
 Why?
Angiomyolipoma
1
2011
21
0.350
 Why?
Carcinoma, Non-Small-Cell Lung
3
2025
1180
0.340
 Why?
Androgen Antagonists
3
2020
91
0.340
 Why?
Deoxycytidine
2
2010
221
0.330
 Why?
Multicenter Studies as Topic
1
2012
405
0.320
 Why?
Benzenesulfonates
1
2010
21
0.320
 Why?
Suramin
1
2010
7
0.320
 Why?
Adult
27
2025
40449
0.320
 Why?
Lung Neoplasms
4
2025
2637
0.320
 Why?
Maximum Tolerated Dose
6
2022
212
0.290
 Why?
Radiosurgery
3
2019
400
0.280
 Why?
Female
35
2026
78271
0.280
 Why?
Immunotherapy
5
2024
653
0.280
 Why?
Indenes
2
2025
6
0.270
 Why?
Fluorouracil
1
2008
235
0.270
 Why?
Disease Progression
3
2021
2847
0.260
 Why?
Bone Neoplasms
2
2023
253
0.260
 Why?
Quinazolines
1
2008
266
0.260
 Why?
Chemotherapy, Adjuvant
3
2013
421
0.250
 Why?
Neoplasm Staging
7
2017
1462
0.250
 Why?
Practice Guidelines as Topic
4
2024
1560
0.240
 Why?
Platinum
2
2024
50
0.240
 Why?
Drug Administration Schedule
3
2021
779
0.240
 Why?
Thyroid Neoplasms
1
2010
345
0.230
 Why?
Proto-Oncogene Proteins c-kit
1
2026
72
0.230
 Why?
Sulfones
2
2017
127
0.220
 Why?
B7-H1 Antigen
2
2025
241
0.220
 Why?
Microsatellite Instability
1
2025
54
0.220
 Why?
Prognosis
5
2023
4282
0.220
 Why?
Phenylurea Compounds
4
2016
112
0.220
 Why?
Benzoxazoles
2
2022
20
0.200
 Why?
Ipilimumab
2
2021
39
0.200
 Why?
Melanoma
2
2025
761
0.200
 Why?
Taste
1
2026
239
0.200
 Why?
Taxoids
2
2017
116
0.200
 Why?
Taste Buds
1
2026
212
0.200
 Why?
Bevacizumab
2
2020
167
0.190
 Why?
Multiple Sclerosis
2
2019
484
0.190
 Why?
Kaplan-Meier Estimate
5
2024
965
0.180
 Why?
Mastectomy
1
2023
162
0.180
 Why?
Quantitative Trait Loci
1
2024
374
0.180
 Why?
Pyrimidines
3
2022
532
0.180
 Why?
Remission, Spontaneous
1
2021
40
0.170
 Why?
Administration, Oral
4
2024
847
0.170
 Why?
Biliary Tract Neoplasms
1
2021
30
0.170
 Why?
Celecoxib
2
2012
41
0.160
 Why?
Neoplasm, Residual
1
2021
139
0.160
 Why?
Carboplatin
1
2021
160
0.160
 Why?
Bariatric Surgery
1
2024
242
0.160
 Why?
Phosphatidylinositol 3-Kinases
1
2022
380
0.160
 Why?
Syndrome
1
2021
380
0.160
 Why?
Proto-Oncogene Proteins c-akt
1
2022
436
0.160
 Why?
Combined Modality Therapy
4
2019
1266
0.160
 Why?
Quality of Life
2
2025
3185
0.160
 Why?
Genomics
1
2025
834
0.150
 Why?
Azepines
1
2020
107
0.150
 Why?
Cancer Care Facilities
1
2020
48
0.150
 Why?
Antiemetics
1
2020
49
0.150
 Why?
Thrombosis
1
2023
393
0.150
 Why?
Homologous Recombination
1
2019
36
0.150
 Why?
Fatal Outcome
1
2020
307
0.150
 Why?
TOR Serine-Threonine Kinases
1
2022
449
0.150
 Why?
Morpholines
1
2020
128
0.150
 Why?
MAP Kinase Kinase Kinases
1
2019
70
0.150
 Why?
Pharyngitis
1
2019
25
0.140
 Why?
Streptococcus
1
2019
29
0.140
 Why?
Anti-Bacterial Agents
2
2020
1907
0.140
 Why?
Disease-Free Survival
4
2016
769
0.140
 Why?
Fruit and Vegetable Juices
1
2018
21
0.140
 Why?
Drug Hypersensitivity
1
2020
90
0.140
 Why?
Diagnosis, Computer-Assisted
1
2019
91
0.140
 Why?
Feedback
1
2019
181
0.140
 Why?
Mutation
2
2025
4089
0.140
 Why?
Indans
1
2017
13
0.140
 Why?
Neoplastic Cells, Circulating
2
2016
81
0.130
 Why?
Cost-Benefit Analysis
1
2021
634
0.130
 Why?
Interferon beta-1b
1
2017
2
0.130
 Why?
Pancreatic Neoplasms
1
2026
919
0.130
 Why?
Niacinamide
3
2016
86
0.130
 Why?
Genome-Wide Association Study
1
2024
1406
0.130
 Why?
Proton Therapy
1
2017
15
0.130
 Why?
Liver Neoplasms
1
2023
780
0.130
 Why?
Erythrocytes, Abnormal
1
2016
14
0.130
 Why?
Polymorphism, Single Nucleotide
1
2024
2145
0.120
 Why?
Dose-Response Relationship, Drug
3
2022
2027
0.120
 Why?
Hematologic Diseases
1
2016
66
0.120
 Why?
Streptococcal Infections
1
2019
168
0.120
 Why?
Multiple Sclerosis, Relapsing-Remitting
1
2017
82
0.120
 Why?
DNA Damage
1
2019
430
0.120
 Why?
Cell Line, Tumor
3
2020
3540
0.120
 Why?
Neoadjuvant Therapy
2
2023
462
0.120
 Why?
Oncolytic Virotherapy
1
2015
13
0.120
 Why?
Indazoles
2
2015
80
0.120
 Why?
Problem Solving
1
2017
156
0.120
 Why?
Mammalian orthoreovirus 3
1
2015
38
0.120
 Why?
Autoimmune Diseases
1
2020
463
0.120
 Why?
Angiopoietin-1
1
2015
12
0.110
 Why?
Angiopoietin-2
1
2015
15
0.110
 Why?
Pyrroles
1
2016
217
0.110
 Why?
Genetic Predisposition to Disease
1
2024
2363
0.110
 Why?
Fatigue
2
2022
366
0.110
 Why?
Receptor, IGF Type 1
1
2015
64
0.110
 Why?
Kidney Glomerulus
1
2015
128
0.110
 Why?
Imidazoles
2
2015
254
0.110
 Why?
Radiation Tolerance
1
2015
103
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2015
253
0.110
 Why?
Nanoparticles
1
2021
519
0.110
 Why?
Soft Tissue Neoplasms
1
2015
127
0.100
 Why?
Severity of Illness Index
2
2019
2925
0.100
 Why?
Magnetic Resonance Imaging
2
2021
3863
0.100
 Why?
Prefrontal Cortex
1
2017
328
0.100
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
109
0.100
 Why?
Prostatectomy
1
2013
93
0.100
 Why?
Patient Satisfaction
1
2017
704
0.100
 Why?
Glycine
1
2014
187
0.090
 Why?
Indoles
1
2016
501
0.090
 Why?
Cohort Studies
5
2021
5960
0.090
 Why?
Recombinant Fusion Proteins
1
2015
675
0.090
 Why?
Glomerular Filtration Rate
1
2015
760
0.090
 Why?
Tubulin Modulators
1
2011
11
0.090
 Why?
Quinolines
1
2013
193
0.090
 Why?
Metabolic Clearance Rate
1
2011
114
0.090
 Why?
Emotions
1
2017
578
0.090
 Why?
Algorithms
1
2019
1837
0.080
 Why?
Arthralgia
1
2011
61
0.080
 Why?
Area Under Curve
1
2011
330
0.080
 Why?
Clinical Trials as Topic
1
2015
1053
0.080
 Why?
Peripheral Nervous System Diseases
1
2011
133
0.080
 Why?
Diarrhea
1
2011
192
0.080
 Why?
Mechanistic Target of Rapamycin Complex 1
2
2022
139
0.080
 Why?
Breast Neoplasms
1
2023
2452
0.080
 Why?
Molecular Structure
1
2011
499
0.080
 Why?
Proto-Oncogene Proteins c-ret
1
2010
40
0.080
 Why?
Biopsy
1
2013
1075
0.080
 Why?
Survival Rate
3
2020
2089
0.080
 Why?
Nomograms
1
2010
59
0.070
 Why?
Tomography, X-Ray Computed
3
2022
2730
0.070
 Why?
Decision Making
1
2017
975
0.070
 Why?
Immunohistochemistry
1
2013
1716
0.070
 Why?
Radiotherapy, Adjuvant
1
2010
222
0.070
 Why?
Drug Synergism
1
2010
357
0.070
 Why?
Capecitabine
1
2008
57
0.070
 Why?
Infusions, Intravenous
1
2010
423
0.070
 Why?
Adenine
2
2022
339
0.070
 Why?
Positron-Emission Tomography
1
2010
323
0.070
 Why?
Proteinuria
1
2008
102
0.070
 Why?
Hypertension, Pregnancy-Induced
1
2008
67
0.060
 Why?
Dysgeusia
1
2026
5
0.060
 Why?
Young Adult
4
2024
14105
0.060
 Why?
Follow-Up Studies
3
2020
5408
0.060
 Why?
Creatinine
1
2008
506
0.060
 Why?
Risk
1
2008
911
0.060
 Why?
Optical Illusions
1
2005
2
0.060
 Why?
Urothelium
1
2025
33
0.060
 Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2024
16
0.050
 Why?
Risk Factors
2
2020
10779
0.050
 Why?
Cell Lineage
1
2026
376
0.050
 Why?
Cytoreduction Surgical Procedures
1
2024
67
0.050
 Why?
Prospective Studies
3
2021
7990
0.050
 Why?
Mastectomy, Segmental
1
2023
108
0.050
 Why?
Adjuvants, Immunologic
1
2024
245
0.050
 Why?
RNA Interference
1
2024
476
0.050
 Why?
Cardiovascular Diseases
1
2014
2168
0.050
 Why?
Disease Management
2
2017
645
0.040
 Why?
RNA, Small Interfering
1
2024
635
0.040
 Why?
Cisplatin
1
2023
334
0.040
 Why?
Nephritis, Interstitial
1
2020
11
0.040
 Why?
International Agencies
1
2020
30
0.040
 Why?
Drug Evaluation
1
2020
79
0.040
 Why?
Aurora Kinase A
1
2020
62
0.040
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
63
0.040
 Why?
Lymphocytes
1
2022
382
0.040
 Why?
Nausea
1
2020
111
0.040
 Why?
Analysis of Variance
2
2017
1306
0.040
 Why?
Hong Kong
1
2019
8
0.040
 Why?
Vomiting
1
2020
130
0.040
 Why?
Lymphatic Metastasis
1
2020
333
0.040
 Why?
Time Factors
1
2010
7173
0.040
 Why?
Sex Factors
1
2025
2112
0.040
 Why?
Mice, Knockout
1
2026
3121
0.040
 Why?
Hospitals
1
2023
730
0.040
 Why?
Medical Oncology
1
2022
332
0.040
 Why?
DNA-Binding Proteins
1
2026
1499
0.030
 Why?
Cell Differentiation
1
2026
2050
0.030
 Why?
Central Nervous System
1
2020
281
0.030
 Why?
Transcription Factors
1
2026
1741
0.030
 Why?
Genetic Testing
1
2020
478
0.030
 Why?
Retreatment
1
2017
77
0.030
 Why?
Databases, Factual
1
2023
1486
0.030
 Why?
Drug Therapy, Combination
1
2020
1047
0.030
 Why?
United States
2
2017
15966
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
52
0.030
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
230
0.030
 Why?
Xenograft Model Antitumor Assays
1
2020
928
0.030
 Why?
Erythrocyte Indices
1
2016
33
0.030
 Why?
Academic Medical Centers
1
2020
547
0.030
 Why?
Antimicrobial Stewardship
1
2019
129
0.030
 Why?
Anti-Inflammatory Agents
1
2020
474
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2019
257
0.030
 Why?
Case-Control Studies
1
2024
3604
0.030
 Why?
Clinical Decision-Making
1
2019
359
0.030
 Why?
Neutrophils
1
2022
1134
0.030
 Why?
Mice
2
2026
18339
0.030
 Why?
Acute Disease
1
2019
1030
0.030
 Why?
Thoracic Neoplasms
1
2015
39
0.030
 Why?
Abdominal Neoplasms
1
2015
47
0.030
 Why?
Tosyl Compounds
1
2015
16
0.030
 Why?
Antibodies, Neoplasm
1
2015
34
0.030
 Why?
Kidney Function Tests
1
2015
157
0.030
 Why?
Reaction Time
1
2017
438
0.030
 Why?
Craniocerebral Trauma
1
2017
176
0.030
 Why?
Angiogenesis Inhibitors
1
2016
237
0.030
 Why?
Neoplasm Grading
1
2015
307
0.030
 Why?
Radiotherapy
1
2015
206
0.030
 Why?
Organ Size
1
2015
463
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
149
0.030
 Why?
Postoperative Period
1
2015
354
0.030
 Why?
Drug Resistance, Neoplasm
1
2020
881
0.030
 Why?
Demography
1
2015
288
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
141
0.030
 Why?
STAT5 Transcription Factor
1
2014
52
0.030
 Why?
Animals
3
2026
38058
0.030
 Why?
Nitriles
1
2015
205
0.030
 Why?
Recurrence
1
2017
1135
0.030
 Why?
Drug Interactions
1
2015
398
0.030
 Why?
Gonadotropin-Releasing Hormone
1
2015
212
0.020
 Why?
Medication Adherence
1
2017
539
0.020
 Why?
ErbB Receptors
1
2015
627
0.020
 Why?
Cell Survival
1
2015
1098
0.020
 Why?
Longitudinal Studies
1
2020
2947
0.020
 Why?
Proportional Hazards Models
1
2015
1325
0.020
 Why?
Neuropsychological Tests
1
2017
1134
0.020
 Why?
Double-Blind Method
1
2016
2029
0.020
 Why?
T-Lymphocytes, Regulatory
1
2014
389
0.020
 Why?
Molecular Targeted Therapy
1
2014
432
0.020
 Why?
Proto-Oncogene Proteins
1
2014
623
0.020
 Why?
Biomarkers
1
2022
4271
0.020
 Why?
Enzyme Inhibitors
1
2014
824
0.020
 Why?
Cell Cycle Proteins
1
2014
628
0.020
 Why?
Logistic Models
1
2015
2117
0.020
 Why?
Reagent Strips
1
2008
8
0.020
 Why?
Primary Health Care
1
2019
1733
0.020
 Why?
Urinalysis
1
2008
80
0.020
 Why?
Albuminuria
1
2008
190
0.020
 Why?
Diagnostic Tests, Routine
1
2008
108
0.020
 Why?
Vision, Monocular
1
2005
4
0.010
 Why?
Psychophysics
1
2005
15
0.010
 Why?
Eye Enucleation
1
2005
14
0.010
 Why?
Vision, Binocular
1
2005
47
0.010
 Why?
Orientation
1
2005
50
0.010
 Why?
Adolescent
2
2020
22428
0.010
 Why?
Pattern Recognition, Visual
1
2005
105
0.010
 Why?
Photic Stimulation
1
2005
264
0.010
 Why?
Sensitivity and Specificity
1
2008
1985
0.010
 Why?
Signal Transduction
1
2014
5226
0.010
 Why?
Pregnancy
1
2008
7190
0.010
 Why?
Child
1
2005
22633
0.000
 Why?
Lam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (314) concept(s)
_
Co-Authors Expand Description
See all (50) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)